Century Therapeutics is developing novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies.

Our commitment to developing accessible cell therapies provides an unparalleled opportunity to advance the course of cancer care.


We harness the power of adult stem cells to 

develop curative therapies for cancer. 


Our dedicated team is developing novel allogeneic living cell products for oncology that overcome the limitations of first-generation cell therapies.

We want to change cancer therapy for good.

For the better, for everyone.


Osvaldo (Lalo) Flores is Chief Executive Officer of Century Therapeutics. He was previously Vice President of R&D and Entrepreneur-in-Residence with Janssen (Johnson & Johnson). He assumed those roles after completing the acquisition and integration of Novira Therapeutics, where he was a co-founder, the President and Chief Scientific Officer. Prior to Novira, Lalo was a department head at Merck & Co., where he led drug discovery and development programs across diverse therapeutic areas including antiviral, oncology and metabolic. He started his R&D career at Tularik Inc., establishing key elements of the antiviral drug discovery platform. Lalo received his PhD in Biochemistry and Molecular Biology from Rutgers University and was a postdoctoral Fellow at the Salk Institute.

Lalo Flores 2

Lalo Flores, PhD


Hy Levitsky is President of Research and Development at Century Therapeutics. He was previously Executive Vice President and Chief Scientific Officer at Juno Therapeutics in Seattle, and before that, Head of Cancer Immunotherapy Experimental Medicine at Roche Pharma Research and Early Development in Switzerland. He received an MD from Johns Hopkins University School of Medicine in 1984, followed by training in internal medicine and medical oncology. He joined the Johns Hopkins faculty in 1991, rising to Professor of Oncology, Medicine and Urology in 2001 while working at the Sidney Kimmel Comprehensive Cancer Center where he served as Scientific Director of the George Santos Bone Marrow Transplant Program. Upon joining industry, he has held an adjunct professorship since 2011. His research has focused on tumor immunology, cancer vaccines, and adoptive T cell therapy. He is a Leukemia and Lymphoma Society Stohlman Scholar, a Member of the American Society for Clinical Investigation, and is a founding member of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

Hy Levitsky n

Hy Levitsky, MD

President of Research & Development

Luis Borges is Chief Scientific Officer at Century Therapeutics. At Century, Luis oversees the research and clinical candidate selection of genetically engineered induced pluripotent stem cell (iPSC)-derived immune cell products to treat hematologic and solid tumors. Before joining Century, Luis developed a pipeline of novel CAR-celltherapies and managed a collaboration with the Baylor College of Medicine to develop allogeneic CAR-NKT cells at Cell Medica. Prior to joining Cell Medica, Luis served as SVP of Research at Five Prime Therapeutics, where he helped transition the company into cancer immunotherapy. In three years at Five Prime, Luis re-shaped and grew the research organization. His group transitioned three novel drug candidates from discovery into investigational new drug (IND)-enabling studies with two of them reaching the clinic. Before joining Five Prime, Luis led numerous drug development teams at Immunex and Amgen. He received his PhD from the University of Washington, Seattle.

Luis Borges n

Luis Borges, PhD

Chief Scientific Officer

Adrienne Farid is Century’s Chief Development Officer. She joined Century from Celgene, where she was Corporate Vice President, Project Leadership and Business Operations in Research & Early Development. Her group ran early development teams, in the past few years filing >20 Investigational New Drug (IND)/Clinical Trial Applications (CTAs) and progressing numerous Phase 1/2 assets in hematology, oncology, and inflammation/immunology. Adrienne was co-lead of the global Liso-cel development team with Juno Therapeutics from 2015-2017, and as part of collaboration governance, she was instrumental in contributing to Celgene’s cell therapy strategies. She led Celgene’s integration of Juno Therapeutics in 2018. Earlier, Adrienne led global development teams, including Pomalyst® in relapsed/refractory multiple myeloma through registration. At Roche for 15 years, she advanced through technical and global development leadership. She began her career at SmithKline Beecham. Adrienne received her Ph.D. in Chemistry from Columbia University, followed by postdoctoral studies at California Institute of Technology.

Adrienne Farid 2

Adrienne Farid, PhD

Chief Development Officer

Greg Russotti is the Chief Technology Officer at Century Therapeutics. Before joining Century, Greg was Vice President of Cell Therapy Development and Operations at Celgene. During his tenure there, he guided CMC efforts for five different cell therapy products to IND and clinical stage development. Greg was also a leader in establishing in-house clinical manufacturing at Celgene, and in building Celgene’s first commercial CAR T manufacturing facility. Prior to Celgene, Greg held various leadership roles at Merck Research Laboratories, developing vaccines and monoclonal antibodies for clinical and commercial manufacturing. Greg received his BS and MS degrees in Chemical Engineering from Rensselaer Polytechnic Institute and his PhD in Chemical and Biochemical Engineering from Rutgers University. He has held a visiting professorship in Rutgers Biomedical Engineering department since 2008. Greg also serves as Industrial Executive Board Chairman of the Marcus Center for the Commercialization of Cell Therapies at Georgia Tech, and as an Executive Committee member of the NSF-funded Center for the Manufacturing of Advanced Therapeutics at Georgia Tech.

Greg Rusotti

Greg Russotti, PhD

Chief Technology Officer

Janelle Anderson is the Chief Strategy Officer at Century Therapeutics. Most recently, Janelle was an Entrepreneur-in-Residence with Versant Ventures and was instrumental in establishing Century’s funding and core technology transactions. Janelle drives the execution of deals and external partnerships which enable Century’s scientific objectives and further its strategic goals. Janelle began her career as a management consultant in the healthcare practice at the Boston Consulting Group (BCG) before taking on various operational and deal-making positions in medical venture capital, including serving as interim CEO of Access Scientific whilst at Carrot Capital. At Merck, Janelle co-founded Merck’s corporate venture group focused on therapeutics (MRL Ventures), led the business integration of external discovery programs, and oversaw finance planning and analysis for Biologics and Vaccines R&D. Prior to joining Versant, Janelle was a Managing Partner at CTI Life Sciences Fund, where she led all US biotech transactions. Janelle earned her B.Sc. in Chemistry (Honors) from McGill University, and A.M. and Ph.D. from the Department of Chemistry and Chemical Biology at Harvard University.

Janelle Anderson 2

Janelle Anderson, PhD

Chief Strategy Officer

Shane Williams is Century Therapeutics’ Chief People Officer and is responsible for the talent agenda, culture, and HR systems. Prior to Century, Shane was the Head of HR Business Partners at QIAGEN, where he supported the Executive Committee on people-related topics. He and his team led global HR initiatives, including Diversity and Inclusion programs, competency mapping, annual compensation management, and the coordination of efficiency objectives. Before joining QIAGEN, Shane held positions with Boston Consulting Group (BCG) in an operational capacity, and with EgonZehnder where was a core member the management appraisal practice and conducted executive searches for global biopharmaceutical clients. Shane spent five years with Elan Pharmaceuticals, as the General manager of PRIALT (an innovative biologic for chronic pain) and in strategy leadership roles. He began his career as a consultant with BCG. Shane received his Ph.D. in Biochemistry from Cambridge University, followed by postdoctoral research at Harvard-MIT Health Sciences and Technology.

Shane Williams 2

Shane Williams, PhD

Chief People Officer

Douglas Carr is Vice President of Finance and Operations at Century Therapeutics. Prior to joining Century, he was VP of Finance at Novira Therapeutics, Inc., where he directed all financial and fiscal management aspects of the Company’s operations and played a key role in the sale of the Company to J&J in December 2015. Before Novira, he was Financial Controller for Omthera Pharmaceuticals, Inc. where he established the finance and accounting infrastructure and led the Company through an initial public offering and subsequent sale to Astra Zeneca in 2013. Prior to Omthera, Douglas spent 15 years at Merck primarily providing financial leadership to various commercial franchises. He began his career at PriceWaterhouseCoopers (previously Coopers&Lybrand). Douglas holds a BA from Rutgers University and is a Certified Public Accountant in the State of New Jersey. He currently serves on the Board of Directors at Heritage Conservancy in Doylestown, Pennsylvania.

Douglas Carr 2

Douglas Carr, CPA

VP Finance & Operations

Michael Naso is Vice President of Cell Engineering at Century Therapeutics, where he leads early discovery efforts to identify engineered cell therapy products for clinical development. Michael was a Director of Cell and Gene Therapy at Janssen Research and Development, leading Janssen’s first gene and cell therapy discovery group. In that role, he initiated Janssens first gene therapy programs utilizing rAAV technology and their first engineered cell therapy efforts toward an allogeneic, off-the-shelf platform. His time in that role led to the identification of novel tumor targeting technologies and engineered cell therapy platforms. While at Janssen and Centocor, he also played important discovery roles bringing numerous product candidates into early development and was part of the discovery teams that launched Remicade, Stelara, Simponi and Tremfya. Michael holds a Ph.D from Thomas Jefferson University in Biochemistry and Molecular Biology.

Michael Naso 2

Michael Naso, PhD

VP Cell Engineering

Carl Burke is Vice President of Development and Manufacturing at Century Therapeutics. Before joining Century, Carl developed and manufactured allogeneic and autologous cell therapies and their regulatory filings at Janssen. Carl started his career at Merck in 1990 responsible for protein and vaccine product development and involved analytical characterization, formulation and filling process development, technology transfer and marketed product support. This work contributed to the successful licensure and post-approval support of many vaccines. Carl joined Janssen in 2008 and initially led the drug product development area for biologics and parenterals. Afterwards, he moved to the Netherlands to lead the vaccines development in Janssen Vaccines, which included all CMC development activities and pilot plants. Upon returning to the US, Carl led the team integrating novel cell therapy process operations as they transitioned to manufacturing.

Carl Burke n

Carl Burke, PhD

VP Development & Manufacturing


Osvaldo (Lalo) Flores is Chief Executive Officer of Century Therapeutics. He was previously Vice President of R&D and Entrepreneur-in-Residence with Janssen (Johnson & Johnson). He assumed those roles after completing the acquisition and integration of Novira Therapeutics, where he was a co-founder, the President and Chief Scientific Officer. Prior to Novira, Lalo was a department head at Merck & Co., where he led drug discovery and development programs across diverse therapeutic areas including antiviral, oncology and metabolic. He started his R&D career at Tularik Inc., establishing key elements of the antiviral drug discovery platform. Lalo received his PhD in Biochemistry and Molecular Biology from Rutgers University and was a postdoctoral Fellow at the Salk Institute.

Lalo Flores 2

Lalo Flores, PhD

CEO at Century Therapeutics

Carlo Rizzuto is a Partner with Versant Ventures and focuses on biotech investing and company building. Carlo joined Versant from Novartis Pharmaceuticals where he led global product development teams in the advancement of innovative pipeline products. He previously held the position of Associate Principal with McKinsey & Company advising US and European clients in the pharmaceutical, payor and provider sectors. Prior to joining McKinsey, Carlo helped found engeneOS, a Boston-based biotech startup. Carlo received a PhD in Virology from Harvard University and a BA in Biology from the University of Virginia.

Carlo Rizzuto 2

Carlo Rizzuto, PhD

Partner at Versant Ventures

Toshikazu Ban is the Corporate Vice President of FUJIFILM Corporation and Deputy General Manager of the pharmaceutical product division. He was previously the Senior Vice President of Global Business Development at Takeda Pharmaceuticals, Inc., where he had held several other positions in R&D Management, Licensing and Business Development in Japan and the U.S. Since joining FUJIFILM in 2013, Toshikazu has been involved in business development activities for pharmaceutical and regenerative medicine products on a global scale. He is currently a Board Member of FUJIFILM Toyama Chemical, FUJIFILM Kyowa Kirin Biologics and Japan Tissue Engineering. Toshikazu earned his Bachelor in Pharmaceutical Science from The University of Tokyo and Master of Science from the Graduate School of Medical Science of Kyoto University.

Toshikazu Ban 2

Toshikazu Ban

Corporate VP, General Manager of Regenerative Medicine Business Division at Fujifilm Corporation

Joe Jimenez is Co-Founder and Managing Partner at Aditum Bio, a biotech venture firm. From 2010 to 2018, Mr. Jimenez held the position of Chief Executive Officer (CEO) of Novartis, one of the world’s leading pharmaceutical companies. Under his leadership, Novartis developed one of the largest pipelines of self-originated drugs in the industry, driven by a strong commitment to R&D. Mr. Jimenez also transformed the company’s portfolio to focus on innovative patented medicines under Novartis Pharmaceuticals and Novartis Oncology, generics under Sandoz, and eye care devices under Alcon. Mr. Jimenez is currently a member of the Board of Directors of General Motors Company, The Proctor & Gamble Company, and Century Therapeutics. Additionally, he served on the Board of Directors of Colgate-Palmolive Company from 2009 to 2015, and of AstraZeneca PLC, from 2002 to 2007. He graduated in 1982 with a bachelor’s degree from Stanford University and in 1984 with a Master of Business Administration from the University of California, Berkeley.

Joe Jimenez

Joe Jimenez, MBA

Co-Founder and Managing Partner at Aditum Bio

Dr. Jak Knowles joined Leaps by Bayer as Vice President of Venture Investments in 2018. Prior to joining Bayer Jak served as CEO of CytoSen Therapeutics, Inc. a cancer immunotherapy company focused on developing Natural Killer cell therapies for oncology indications. In 2016, Jak co-founded and launched Exonics Therapeutics, a CRISPR gene-editing company focused on delivering therapies for Duchenne muscular dystrophy, and served as President and interim CEO. Jak has a medical degree from Stanford University where he graduated with honors in biomedical research, and has had a career in healthcare investing spanning over a decade. Jak has previously served on the Board of Directors for the pharma biotech companies CytoSen Therapeutics, Exonics Therapeutics, Myotherix and RASRx, and for TRiNDS, a neuromuscular focused CRO.

Jak Knowles 2

Jak Knowles, MD

Vice President Venture Investments at Bayer

Scientific Co-founders

Dr. Marcela Maus is the Director of Cellular Immunotherapy at the Massachusetts General Hospital Cancer Center and an Attending Physician in the Bone Marrow Transplant and Cell Therapy division of Oncology at the Massachusetts General Hospital. Dr. Maus is an Assistant Professor at Harvard Medical School, an Associate Member of the Broad Institute of Harvard and MIT, and an Associate Member of the Ragon Institute of MGH, MIT, and Harvard.

She is a translational physician-scientist in the field of immunology, particularly as it relates to cancer. Her lab focuses on the design, generation, and use of innovative forms of immune cell engineering, including chimeric antigen receptors. Her laboratory investigates basic mechanisms of human immunology to design and test novel immune-based therapeutic interventions in vitro, in mouse models, and in patients.

Dr. Maus received her S.B. from the Massachusetts Institute of Technology, and her M.D. and Ph.D. degrees from the University of Pennsylvania. Dr. Maus trained in internal medicine at University of Pennsylvania and in hematology and medical oncology at Memorial Sloan Kettering, and is board-certified in these three disciplines.

Marcela Maus 2

Marcela Maus, MD, PhD

Assistant Professor of Medicine, Harvard Medical School/MGH Cancer Center & Director of Cellular Immunotherapy

The focal point of Hiro’s work is the translation of discoveries in basic research into practical medical applications. After earning an M.D. and a Ph.D. in immunology, Dr. Nakauchi came to Stanford University as a postdoctoral scholar and isolated CD8 genes. After returning to Japan, he started working on hematopoietic stem cells in his laboratory at RIKEN. In 1994, he became a Professor of Immunology at the University of Tsukuba where he demonstrated that a single hematopoietic stem cell could reconstitute the entire hematopoietic system, a definitive experimental proof for the “stemness”. In 2002, he became a Professor of Stem Cell Therapy in the Institute of Medical Science at The University of Tokyo (IMSUT). In 2008, he was appointed Director of the newly established Center for Stem Cell Biology and Regenerative Medicine at IMSUT. In 2014, he returned to Stanford University as a faculty to continue his stem cell research at the Institute of Stem Cell Biology and Regenerative Medicine.

Hiromitzu Nakauchi 2

Hiromitsu (Hiro) Nakauchi, MD, PhD

Professor of Genetics, Stanford University School of Medicine


Leaps by Bayer is spearheading a movement to make paradigm-shifting advances in the life sciences—targeting the breakthroughs that could fundamentally change the world for the better.

Leaps logo RZ RGB

FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human induced pluripotent stem cells (iPSC) utilized in drug discovery and cell therapies. The pre-clinical stage company is using its expertise in iPSC technologies to develop a robust cell therapeutics pipeline to address unmet medical needs in areas such as age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, congestive heart failure, and immuno-oncology. For its partners, FCDI utilizes its iPSC platform to advance the progress of therapeutic candidates in the clinic and provides contract development and manufacturing (CDMO) services. In addition to cell therapy, FCDI also offers life science research tools including the company’s inventoried iCell® products are available in almost any cell type and they are sourced from multiple cell lines which can be applied for target identification as well as toxicity testing. The company also offers custom cell services and cell banking. FCDI’s goal is to leverage the vast utility of iPSC to advance human health and improve the quality of life for patients around the world.


Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With USD3 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and clinical expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 70 Versant companies have achieved successful acquisitions or IPOs.

VER Logo 2c RGB 01
© Century Therapeutics 2020 | Legal